Incyte (INCY) Expected to Announce Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY) is expected to announce its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of $1.40 per share and revenue of $1.2346 billion for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). The company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The company’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.43 earnings per share. On average, analysts expect Incyte to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Incyte Trading Down 0.9%

Shares of Incyte stock opened at $94.65 on Friday. The stock has a market cap of $18.84 billion, a P/E ratio of 14.77, a P/E/G ratio of 0.76 and a beta of 0.85. The stock’s 50 day simple moving average is $96.09 and its 200-day simple moving average is $98.49. Incyte has a 1-year low of $57.77 and a 1-year high of $112.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25.

Insider Transactions at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $96.50, for a total value of $1,801,365.50. Following the sale, the insider owned 262,692 shares of the company’s stock, valued at $25,349,778. The trade was a 6.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.80% of the stock is currently owned by insiders.

Institutional Trading of Incyte

A number of large investors have recently modified their holdings of the stock. Invesco Ltd. increased its position in shares of Incyte by 13.2% during the fourth quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company’s stock worth $343,105,000 after acquiring an additional 405,611 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Incyte by 13.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,103,946 shares of the biopharmaceutical company’s stock worth $263,246,000 after acquiring an additional 373,298 shares during the period. Morgan Stanley increased its position in shares of Incyte by 0.9% during the fourth quarter. Morgan Stanley now owns 2,663,823 shares of the biopharmaceutical company’s stock worth $263,106,000 after acquiring an additional 23,087 shares during the period. Jacobs Levy Equity Management Inc. increased its position in shares of Incyte by 31.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,284,317 shares of the biopharmaceutical company’s stock worth $225,622,000 after acquiring an additional 540,523 shares during the period. Finally, Man Group plc increased its position in shares of Incyte by 20.0% during the third quarter. Man Group plc now owns 1,933,547 shares of the biopharmaceutical company’s stock worth $163,984,000 after acquiring an additional 322,877 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on INCY shares. UBS Group reduced their price target on shares of Incyte from $104.00 to $94.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler lifted their price target on shares of Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Morgan Stanley set a $102.00 price target on shares of Incyte in a research report on Wednesday, February 11th. Wells Fargo & Company reduced their price target on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 11th. Finally, Stifel Nicolaus lifted their price target on shares of Incyte from $119.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Ten equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $104.89.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.